EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

20-Year Experience With Decellularized Pulmonary Homografts for Pulmonary Valve Replacement

Samir Sarikouch iD, Dietmar Boethig, Murat Avsar, Anatol Ciubotaru, Eduard Cheptanaru, Anatolie Cazacu, Philipp Beerbaum, Mechthild Westhoff-Bleck, Serghei Cebotari, Igor Tudorache, Tomislav Cvitkovic, Dmitry Bobylev und 2 weitere

European Journal of Cardio-Thoracic Surgery · 2026

DOI: 10.1093/ejcts/ezag087 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Cardio-Thoracic Surgery, 2026. Verfasst von Samir Sarikouch und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department for Cardiothoracic, Transplant, and Vascular Surgery, Hannover Medical School, 30625 Hannover, Germany. Hauptthemen laut MEDLINE: Pulmonary Valve, Heart Valve Prosthesis Implantation, Heart Valve Prosthesis, Bioprosthesis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CORTISS Hannover, Herz-und Gewebeforschungs-GmbH and Kleine Herzen Westerwald e. V.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Fresh, non-cryopreserved and non-seeded, decellularized pulmonary homografts (DPHs) were translated in 2005 into clinical practice. The aim of this current study is to summarize our 20-year clinical experience with DPH for pulmonary valve replacement (PVR) in congenital heart disease.

Methods

Prospective follow-up of all DPH implanted within 2 institutions. Indication for PVR according to current clinical guidelines was the key inclusion criterion without age limits; patients with active endocarditis were not included.

Results

From January 2005 to August 2025, 310 patients (188 male) received DPH for PVR. Median patient age at implantation was 14.8 years, (interquartile range [IQR] 12.7-16.6 years, min. 0.1 years, max.72.8 years), and the median DPH diameter was 22 mm (IQR 19-23 mm, min. 12 mm, max 34 mm). Median follow-up was 8.3 years (IQR 4.5-12.1, max 20.5 years). Seven out of 310 patients died, a freedom from death according Kaplan-Meier of 96.9% (confidence interval [CI] 93.1%-98.6%) at 20 years. Freedom from DPH explantation was 85.2% (CI 75.1%-91.4%), and freedom from endocarditis was 91.0% (CI 77.1%-96.6%) at 20 years. Valve function showed a steady decline over the study period. At 15 years, freedom from stenosis, as defined as a maximum gradient of ≥ 50 mmHg, was 68.3% (CI 52.4%-79.8%) and 0 at 20 years. Freedom from ≥ moderate pulmonary regurgitation was 65.1% (CI 48.1%-77.7%) at 15 years and 0 at 20 years. The number of patients at risk beyond 15 years was limited.

Conclusions

Decellularized pulmonary homografts show good long-term results for PVR with freedom from explantation that appears favourable compared with published long-term series of cryopreserved homografts. However, our data also indicate a decline in valve function over 2 decades. We hypothesize that residual immunogenicity is the underlying cause, suggesting that there is potential for further refinement of decellularization methods.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary ValveHeart Valve Prosthesis ImplantationHeart Valve ProsthesisBioprosthesisHumansAdolescentChildMaleFemaleAllograftsProspective StudiesHeart Defects, CongenitalFollow-Up Studies

Stichwörter der Autor:innen

allograftschildrendecellularizationpulmonary valve replacement

Autor:innen und Institutionen

  • Department for Cardiothoracic, Transplant, and Vascular Surgery, Hannover Medical School, 30625 Hannover, Germany.
  • Department for Paediatric Cardiology and Paediatric Intensive Care, Hannover Medical School, 30625 Hannover, Germany.
  • Cardiac Surgery Center, State Medical and Pharmaceutical University, MD-2004 Chișinău, Moldova.
  • Centrul Diagnostic German, MD-2001 Chișinău, Moldova.
  • Department for Cardiology and Angiology, Hannover Medical School, 30625 Hannover, Germany.
  • Department of Cardiac Surgery, Institute for Cardiac Surgery and Interventional Cardiology, 1210 Luxembourg, Luxembourg.

ORCID-Profile: Samir Sarikouch

Förderung

  • CORTISS Hannover, Herz-und Gewebeforschungs-GmbH and Kleine Herzen Westerwald e. V

Zitieren

APA

Sarikouch, S., Boethig, D., Avsar, M., Ciubotaru, A., Cheptanaru, E., Cazacu, A., Beerbaum, P., Westhoff-Bleck, M., Cebotari, S., Tudorache, I., Cvitkovic, T., Bobylev, D., Ruhparwar, A., & Horke, A. (2026). 20-Year Experience With Decellularized Pulmonary Homografts for Pulmonary Valve Replacement. European Journal of Cardio-Thoracic Surgery. https://doi.org/10.1093/ejcts/ezag087

Vancouver

Sarikouch S, Boethig D, Avsar M, Ciubotaru A, Cheptanaru E, Cazacu A, et al. 20-Year Experience With Decellularized Pulmonary Homografts for Pulmonary Valve Replacement. European Journal of Cardio-Thoracic Surgery. 2026. doi:10.1093/ejcts/ezag087

BibTeX
@article{Sarikouch2026,
  author = {Sarikouch, Samir and Boethig, Dietmar and Avsar, Murat and Ciubotaru, Anatol and Cheptanaru, Eduard and Cazacu, Anatolie and Beerbaum, Philipp and Westhoff-Bleck, Mechthild and Cebotari, Serghei and Tudorache, Igor and Cvitkovic, Tomislav and Bobylev, Dmitry and Ruhparwar, Arjang and Horke, Alexander},
  title = {20-Year Experience With Decellularized Pulmonary Homografts for Pulmonary Valve Replacement},
  journal = {European Journal of Cardio-Thoracic Surgery},
  year = {2026},
  doi = {10.1093/ejcts/ezag087}
}
Kostenlos starten →